Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742765 | 0.86 | GRM3 (0.59) | CYP2C9CYP2C19FOLH1GRM3 | |
| SCHEMBL14927202 | 0.83 | CYP2C9 (0.60) | CYP2C9CYP2C19FOLH1GRM3 | |
| SCHEMBL5051270 | 0.78 | MMP1 (0.59) | FOLH1 | |
| SCHEMBL7051219 | 0.75 | FOLH1 (0.41) | FOLH1GRM3CHRM1AKR1A1CHRM3 | |
| SCHEMBL5515375 | 0.75 | TDP1 (0.59) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL2742758 | 0.73 | CHRM1 (0.58) | FOLH1GRM3CHRM1AKR1A1CHRM3 | |
| SCHEMBL7051220 | 0.72 | PPARG (0.45) | CYP2C9CYP2C19 | |
| SCHEMBL15965757 | 0.72 | GCLC (0.57) | FOLH1GRM3CHRM1AKR1A1CHRM3 | |
| SCHEMBL5057818 | 0.71 | MMP1 (0.52) | FOLH1 | |
| SCHEMBL9056789 | 0.71 | CYP2C9 (0.64) | CYP2C9CYP2C19CHRM1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125854-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | PFIZER INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9895378-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same | PFIZER INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170151181-A1 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES | PFIZER INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170119672-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods Of Making And Using Same | PFIZER INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170042828-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042855-A1 | NANOPARTICLES COMPRISING DOCETAXEL FOR TREATING CANCERS HAVING A K-RAS MUTATION | BIND THERAPEUTICS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20160338959-A1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2016-11-24 | — | — | US | disclosed |
| US-20150258102-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2015-09-17 | — | — | US | disclosed |
| US-20140249158-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | BIND THERAPEUTICS, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140248358-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | BIND THERAPEUTICS, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140178475-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | BIND THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130251816-A1 | CANCER CELL TARGETING USING NANOPARTICLES | BIND THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248358-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | CD44, NCL, TP53 | CYP2C9 4841/4885CYP2C19 4836/4885FOLH1 40/4885 |
| US-20130251816-A1 | CANCER CELL TARGETING USING NANOPARTICLES | CD47, EPCAM, CD44 | CYP2C9 4468/4885CYP2C19 4474/4885FOLH1 279/4885 |
| US-20150258102-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | TP53, VHL, MTDH | CYP2C9 4813/4885CYP2C19 4740/4885FOLH1 292/4885 |
| US-20140178475-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | CD44, NCL, TP53 | CYP2C9 4841/4885CYP2C19 4836/4885FOLH1 40/4885 |
| US-20160338959-A1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | LDHA, LDHB, LPXN | CYP2C9 2956/4885CYP2C19 3149/4885FOLH1 177/4885 |
| US-20170119672-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods Of Making And Using Same | CD44, NCL, TP53 | CYP2C9 4841/4885CYP2C19 4836/4885FOLH1 40/4885 |
| US-20140249158-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | CD44, NCL, TP53 | CYP2C9 4841/4885CYP2C19 4836/4885FOLH1 40/4885 |
| US-20180125854-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | TP53, HNRNPH3, VHL | CYP2C9 4856/4885CYP2C19 4837/4885FOLH1 336/4885 |
| US-20170042828-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | CD44, NCL, TP53 | CYP2C9 4841/4885CYP2C19 4836/4885FOLH1 40/4885 |
| US-20170151181-A1 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES | KRAS, TP53, NRAS | CYP2C9 4745/4885CYP2C19 4798/4885FOLH1 336/4885 |
| US-20170042855-A1 | NANOPARTICLES COMPRISING DOCETAXEL FOR TREATING CANCERS HAVING A K-RAS MUTATION | KRAS, NRAS, HRAS | CYP2C9 4284/4885CYP2C19 4441/4885FOLH1 1995/4885 |
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | CTSA, GAA, EEA1 | CYP2C9 4878/4885CYP2C19 4872/4885FOLH1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.